Meeder Asset Management Inc. Sells 1,871 Shares of DaVita Inc. (NYSE:DVA)

Meeder Asset Management Inc. reduced its stake in DaVita Inc. (NYSE:DVA) by 72.5% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 710 shares of the company’s stock after selling 1,871 shares during the quarter. Meeder Asset Management Inc.’s holdings in DaVita were worth $98,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently made changes to their positions in the stock. Vanguard Group Inc. boosted its position in shares of DaVita by 2.4% in the 4th quarter. Vanguard Group Inc. now owns 6,320,740 shares of the company’s stock worth $662,161,000 after purchasing an additional 145,711 shares in the last quarter. Gates Capital Management Inc. boosted its position in shares of DaVita by 3.1% in the 4th quarter. Gates Capital Management Inc. now owns 905,830 shares of the company’s stock worth $94,895,000 after purchasing an additional 27,660 shares in the last quarter. 8 Knots Management LLC bought a new stake in shares of DaVita in the 4th quarter worth approximately $89,504,000. Allianz Asset Management GmbH boosted its position in shares of DaVita by 63.9% in the 4th quarter. Allianz Asset Management GmbH now owns 548,642 shares of the company’s stock worth $57,476,000 after purchasing an additional 213,992 shares in the last quarter. Finally, Doma Perpetual Capital Management LLC bought a new stake in shares of DaVita in the 4th quarter worth approximately $53,076,000. 90.12% of the stock is owned by institutional investors.

DaVita Stock Performance

DVA traded down $5.60 during mid-day trading on Monday, reaching $135.95. 777,866 shares of the company traded hands, compared to its average volume of 860,255. The stock has a market capitalization of $11.92 billion, a P/E ratio of 15.45, a P/E/G ratio of 1.08 and a beta of 0.87. The company has a quick ratio of 1.37, a current ratio of 1.43 and a debt-to-equity ratio of 7.95. The company’s fifty day moving average price is $140.23 and its 200-day moving average price is $129.45. DaVita Inc. has a 52-week low of $71.51 and a 52-week high of $147.93.

DaVita (NYSE:DVA) last announced its earnings results on Thursday, May 2nd. The company reported $2.38 earnings per share for the quarter, beating analysts’ consensus estimates of $1.95 by $0.43. The business had revenue of $3.07 billion during the quarter, compared to analyst estimates of $3.03 billion. DaVita had a net margin of 6.61% and a return on equity of 68.52%. The company’s quarterly revenue was up 6.9% compared to the same quarter last year. During the same period in the previous year, the business earned $1.58 EPS. On average, sell-side analysts expect that DaVita Inc. will post 9.62 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the company. Barclays upped their price objective on DaVita from $133.00 to $150.00 and gave the company an “equal weight” rating in a research report on Monday, May 6th. StockNews.com cut DaVita from a “strong-buy” rating to a “buy” rating in a research report on Saturday, June 8th. Finally, Truist Financial upped their price objective on DaVita from $135.00 to $150.00 and gave the company a “hold” rating in a research report on Wednesday, May 15th. Two equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat.com, DaVita has a consensus rating of “Moderate Buy” and a consensus target price of $144.67.

Insider Buying and Selling at DaVita

In other news, Director Barbara J. Desoer sold 5,030 shares of the company’s stock in a transaction on Friday, May 10th. The stock was sold at an average price of $138.81, for a total value of $698,214.30. Following the completion of the sale, the director now directly owns 10,954 shares in the company, valued at approximately $1,520,524.74. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 2.00% of the company’s stock.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.